---
title: "Compugen Announces Interim Analysis Timeline for MAIA-Ovarian Trial of COM701 as Maintenance Therapy in Platinum-Sensitive Ovarian Cancer"
description: "Compugen Ltd. has announced an interim analysis timeline for its MAIA-ovarian trial, evaluating COM701 as a maintenance therapy in platinum-sensitive ovarian cancer. The analysis will occur after data"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/260882686.md"
published_at: "2025-10-13T11:01:18.000Z"
---

# Compugen Announces Interim Analysis Timeline for MAIA-Ovarian Trial of COM701 as Maintenance Therapy in Platinum-Sensitive Ovarian Cancer

> Compugen Ltd. has announced an interim analysis timeline for its MAIA-ovarian trial, evaluating COM701 as a maintenance therapy in platinum-sensitive ovarian cancer. The analysis will occur after data from about 60 participants is collected, with results expected by the end of 2026. Clinical sites have been activated in the U.S., Israel, and France to support enrollment. Additionally, a pooled analysis of COM701 from three Phase 1 trials will be presented at ESMO 2025, with the abstract available on the company’s website and the poster set for release on October 18, 2025.

Compugen Ltd. has announced new developments regarding its clinical programs in ovarian cancer. The company is currently conducting the MAIA-ovarian trial, evaluating COM701 as a maintenance therapy in relapsed platinum-sensitive ovarian cancer. An interim analysis is planned once data from approximately 60 participants are available, with results estimated by year end 2026. To support enrollment, Compugen has activated clinical sites in the U.S., Israel, and France. Additionally, Compugen will present a pooled analysis of COM701 in three Phase 1 trials involving patients with platinum-resistant ovarian cancer at ESMO 2025. The abstract for this analysis is already available on the company’s website, and the poster will be released on October 18, 2025. The pooled analysis provides support for the ongoing MAIA-ovarian trial of COM701. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Compugen Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: IO96101) on October 13, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)

### Related Stocks

- [CGEN.US - Compugen](https://longbridge.com/en/quote/CGEN.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| MAIA Biotech（NYSEAMERICAN:MAIA）股价上涨 0.5% - 你是否应该购买？ | MAIA Biotechnology 的股票（NYSEAMERICAN:MAIA）上涨了 0.5%，至 1.98 美元，交易量较其平均水平下降了 54%。该公司报告的季度每股收益为-0.27 美元，未能达到预期。内部人士最近增加了持股，董事 | [Link](https://longbridge.com/en/news/275416815.md) |
| 芝加哥一名父亲因移民案件被拘留，其女儿因罕见癌症去世 | 16 岁的芝加哥女孩奥菲莉亚·吉赛尔·托雷斯·伊达尔戈因患有第四期肺泡横纹肌肉瘤去世，她在生前积极倡导父亲的移民拘留释放。她的父亲鲁本·托雷斯·马尔多纳多去年秋季因驱逐案件被拘留。在她去世前不久，法官裁定他可以因驱逐对其美国公民子女造成的困 | [Link](https://longbridge.com/en/news/276014113.md) |
| 在雅培提出 105 美元报价后，是否是时候重新评估精密科学（EXAS）？ | 精密科学（Exact Sciences，股票代码：EXAS）目前的交易价格为 103.24 美元，过去一年回报率为 109.4%。分析师建议，根据折现现金流（DCF）分析，该股票被低估了 32%，估计每股内在价值为 151.75 美元。市销 | [Link](https://longbridge.com/en/news/275956793.md) |
| Revolution Medicines 会议：CEO 详细介绍 Daraxonrasib 第三阶段时间表，首次推进胰腺导管腺癌（PDAC） | Revolution Medicines 首席执行官 Mark Goldsmith 在一次会议上讨论了 daraxonrasib 的第三阶段时间表，这是一种 RAS(ON) 抑制剂。针对二线胰腺导管腺癌 (PDAC) 的 RASolute  | [Link](https://longbridge.com/en/news/275992906.md) |
| 众巢医学召开了特别股东大会 | 众巢医学于 2026 年 2 月 10 日召开了特别股东大会。股东们批准了关于 B 类股份的章程修订和增资的提案。此外，待董事会批准的股份合并提案也获得了通过。该信息基于众巢医学通过 EDGAR 发布的内容 | [Link](https://longbridge.com/en/news/275509233.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.